- Home
- ANIP vs EOS Comparison
ANIP vs EOS Comparison
Compare ANIP & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- EOS
- Stock Information
- Founded
- ANIP 2001
- EOS 2005
- Country
- ANIP United States
- EOS United States
- Employees
- ANIP N/A
- EOS N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- EOS Trusts Except Educational Religious and Charitable
- Sector
- ANIP Health Care
- EOS Finance
- Exchange
- ANIP Nasdaq
- EOS Nasdaq
- Market Cap
- ANIP 1.2B
- EOS 1.2B
- IPO Year
- ANIP N/A
- EOS N/A
- Fundamental
- Price
- ANIP $55.67
- EOS $24.21
- Analyst Decision
- ANIP Buy
- EOS
- Analyst Count
- ANIP 7
- EOS 0
- Target Price
- ANIP $77.33
- EOS N/A
- AVG Volume (30 Days)
- ANIP 253.7K
- EOS 84.1K
- Earning Date
- ANIP 11-08-2024
- EOS 01-01-0001
- Dividend Yield
- ANIP N/A
- EOS 6.80%
- EPS Growth
- ANIP N/A
- EOS N/A
- EPS
- ANIP N/A
- EOS N/A
- Revenue
- ANIP $555,456,000.00
- EOS N/A
- Revenue This Year
- ANIP $25.49
- EOS N/A
- Revenue Next Year
- ANIP $19.92
- EOS N/A
- P/E Ratio
- ANIP N/A
- EOS N/A
- Revenue Growth
- ANIP 23.60
- EOS N/A
- 52 Week Low
- ANIP $52.00
- EOS $15.62
- 52 Week High
- ANIP $70.81
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- ANIP 42.29
- EOS 74.70
- Support Level
- ANIP $55.29
- EOS $23.94
- Resistance Level
- ANIP $57.33
- EOS $24.30
- Average True Range (ATR)
- ANIP 1.88
- EOS 0.24
- MACD
- ANIP -0.16
- EOS 0.01
- Stochastic Oscillator
- ANIP 5.34
- EOS 95.22
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. It invests in a portfolio of large and mid-cap securities in the sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.